In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Characterization of 0839 A tool compound for pre clinical mode of action studies of amylin analogues such as cagrilintide ScienceDirect Cagrilintide Wikipedia Cagrilintide is a long acting amylin analog that regulates appetite, gastric emptying, and glucagon secretion to treat obesity and related metabolic disorders. There are 2 pathways cagrilintide works: Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 eBioMedicine Cagrilintide (10mg vials) Peptide Partners